Maureen Newman,  —

Arcturus Therapeutics, Inc. recently presented encouraging non-human primate studies concerning its preclinical messenger RNA therapies for the potential treatment of genetic diseases such as cystic fibrosis at the 2nd International mRNA Health Conference held November 11-12 in Cambridge, Massachusetts. Arcturus’ presentation, “Potent Delivery of LUNAR™ Nanoparticles Containing Synthetic mRNA for…

New ways of treating cystic fibrosis are under development at the University of Dundee. Along with colleagues in Italy, France, and Scotland, Dr. Anil Mehta, a clinical researcher at Dundee’s Medical Research Institute, pioneered a new drug combination that gives hope to patients with cystic fibrosis. “This work shows…

OrPro Therapeutics, Inc. is presenting the newest data concerning its leading pre-clinical therapeutic, ORP-100, at the 28th Annual North American Cystic Fibrosis Conference held October 9-11 in Atlanta. ORP-100 is being developed to treat cystic fibrosis by attacking the pathological, adhesive mucus found in patients’ lungs. According to a…

Young adults and children with cystic fibrosis in the United States have better lung function than those who live in the United Kingdom, despite the fact that both countries have well-developed healthcare systems. Differences in lung function may be a result of differences in healthcare structure, according to the…

Any concern that may exist over cystic fibrosis patients receiving nasal live-attenuated influenza vaccine (LAIV) due to infection risk may be unfounded, according to a new study conducted by Constantina Boikos, MScPH, from McGill University in Montreal. Dr. Boikos and colleagues evaluated 168 cystic fibrosis patients, ages 2 to…

Drug development companies such as NovaBiotics that are devoted to designing and developing treatments for patients with difficult-to-treat, medically unmet diseases are often faced with the hurdle of recruiting enough patients to conduct the clinical trials necessary to approve new treatments. Recently, the hindrance has…

Cystic fibrosis is among the numerous chronic conditions categorized as rare diseases. As many cystic fibrosis patients know, a unique set of burdens are placed upon themselves and their caregivers, and Atlantis Healthcare is working to bring light to patients’ hardships. Recently, Atlantis Healthcare released a white paper with…

Vertex Pharmaceuticals will be presenting 15 abstracts at the 28th Annual North American Cystic Fibrosis Conference (NACFC) held in Atlanta from October 9-11. Each abstract is from Vertex’s cystic fibrosis research and development program. Data will primarily be related to TRAFFIC and TRANSPORT clinical trials, which were phase…

Sildenafil, antioxidants, and gene therapy for cystic fibrosis treatment are part of an arsenal of studies in progress at Medical College of Georgia at Georgia Regents University. At the heart of the action is Dr. Ryan A. Harris, clinical exercise physiologist at the Georgia Prevention Institute at the college.

In light of the news that almost 50% of cystic fibrosis patients are infected with Aspergillus mold, health leaders are reminding patients that it is important to limit exposure to agents that can cause infection for…